ARCELLX INC (ACLX) Stock Price, Quote, News and Overview
NASDAQ:ACLX - Nasdaq - US03940C1009 - Common Stock - Currency: USD
ACLX Quote, Performance and Key Statistics
62.02
+1.33 (+2.19%)
The current stock price of ACLX is 62.02 USD. In the past month the price decreased by -13.13%. In the past year, price increased by 20.08%.
ACLX Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 17.09 | 306.02B | ||
| AMGN | AMGEN INC | 13.99 | 149.08B | ||
| GILD | GILEAD SCIENCES INC | 22.68 | 130.32B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1686.55 | 125.74B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.34 | 61.56B | ||
| ARGX | ARGENX SE - ADR | 320.54 | 36.40B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 30.51B | ||
| ONC | BEIGENE LTD-ADR | N/A | 24.89B | ||
| BNTX | BIONTECH SE-ADR | N/A | 23.74B | ||
| NTRA | NATERA INC | N/A | 20.02B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 18.15B | ||
| BIIB | BIOGEN INC | 7.2 | 17.36B |
Related stock screener links
About ACLX
Company Profile
Arcellx, Inc is a clinical-stage biotechnology company, which provides cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases. The company is headquartered in Redwood City, California and currently employs 163 full-time employees. The company went IPO on 2022-02-04. Its lead program is a BCMA-targeting ddCAR product candidate called anitocabtagene autoleucel, which is being evaluated in its pivotal Phase II iMMagine-1 and the Phase III iMMagine-3 trials in patients with relapsed or refractory multiple myeloma (rrMM). Anitocabtagene is the first BCMA-directed CAR T-cell therapy to be investigated in multiple myeloma that utilizes its novel and compact binder known as the D-Domain. The small, stable D-Domain binder enables high CAR expression without tonic signaling and is designed to quickly release from the BCMA target. The company is also developing two clinical-stage ARC-SparX programs in Phase I trials: ACLX-001, which targets BCMA in rrMM, and ACLX-002, which targets CD123 in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS).
Company Info
ARCELLX INC
800 Bridge Parkway
Redwood City CALIFORNIA US
Employees: 130
Company Website: https://www.arcellx.com/
Investor Relations: https://ir.arcellx.com/
Phone: 12403270603
ARCELLX INC / ACLX FAQ
What is the stock price of ARCELLX INC today?
The current stock price of ACLX is 62.02 USD. The price increased by 2.19% in the last trading session.
What is the ticker symbol for ARCELLX INC stock?
The exchange symbol of ARCELLX INC is ACLX and it is listed on the Nasdaq exchange.
On which exchange is ACLX stock listed?
ACLX stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for ARCELLX INC stock?
25 analysts have analysed ACLX and the average price target is 117.87 USD. This implies a price increase of 90.06% is expected in the next year compared to the current price of 62.02. Check the ARCELLX INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is ARCELLX INC worth?
ARCELLX INC (ACLX) has a market capitalization of 3.41B USD. This makes ACLX a Mid Cap stock.
How many employees does ARCELLX INC have?
ARCELLX INC (ACLX) currently has 130 employees.
What are the support and resistance levels for ARCELLX INC (ACLX) stock?
ARCELLX INC (ACLX) has a support level at 58.83 and a resistance level at 62.03. Check the full technical report for a detailed analysis of ACLX support and resistance levels.
Is ARCELLX INC (ACLX) expected to grow?
The Revenue of ARCELLX INC (ACLX) is expected to decline by -25.46% in the next year. Check the estimates tab for more information on the ACLX EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy ARCELLX INC (ACLX) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of ACLX, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of ACLX, evaluating the profitability, health, valuation and growth aspects
- ARCELLX INC (ACLX) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- ARCELLX INC (ACLX) Sales and EPS estimates to see what analysts future expectations are.
- ARCELLX INC (ACLX) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- ARCELLX INC (ACLX) Insider and Institutional Ownership to learn about the owners and their transactions.
- ARCELLX INC (ACLX) Stock Chart to make your own analysis
- ARCELLX INC (ACLX) Latest news and press-releases to stay up to date.
Does ARCELLX INC (ACLX) stock pay dividends?
ACLX does not pay a dividend.
When does ARCELLX INC (ACLX) report earnings?
ARCELLX INC (ACLX) will report earnings on 2025-05-08, after the market close.
What is the Price/Earnings (PE) ratio of ARCELLX INC (ACLX)?
ARCELLX INC (ACLX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2).
What is the Short Interest ratio of ARCELLX INC (ACLX) stock?
The outstanding short interest for ARCELLX INC (ACLX) is 14.32% of its float. Check the ownership tab for more information on the ACLX short interest.
ACLX Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to ACLX. When comparing the yearly performance of all stocks, ACLX is one of the better performing stocks in the market, outperforming 82.85% of all stocks.
ACLX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ACLX. No worries on liquidiy or solvency for ACLX as it has an excellent financial health rating, but there are worries on the profitability.
ACLX Financial Highlights
Over the last trailing twelve months ACLX reported a non-GAAP Earnings per Share(EPS) of -2. The EPS decreased by -36.05% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -15.09% | ||
| ROE | -23.6% | ||
| Debt/Equity | 0 |
ACLX Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 86% to ACLX. The Buy consensus is the average rating of analysts ratings from 25 analysts.
For the next year, analysts expect an EPS growth of -55.6% and a revenue growth -25.46% for ACLX